Adalvo announces its DCP approval for Adapalene/Benzoyl Peroxide 0.1%/2.5% and 0.3%/2.5% Gel, positioning us as Europe's first and only company to secure approval for both strengths.
Designed for the treatment of acne in adults and adolescents, Adapalene/Benzoyl Peroxide leverages a proven formulation based on the reference brand Epiduo Gel, which reached global sales of $152 million in 2023, according to IQVIA.
Adalvo’s Adapalene/Benzoyl Peroxide Gel provides a cost-efficient tube alternative to pump-container products on the market. Manufactured through a European supply chain, the product emphasises quality while providing a more accessible solution.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!